The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer
Official Title: Activity Monitoring to Improve Patient Care During Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC)
Study ID: NCT04878952
Brief Summary: This trial will examine if the monitoring of daily step counts during a course of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer will enable clinicians to deliver improved supportive care and reduce the rate of adverse events during the course of radiation treatment.
Detailed Description: PRIMARY OBJECTIVE: To demonstrate that monitoring daily step counts during a course of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer will enable clinicians to deliver improved supportive care and reduce the rate of adverse clinical events during the radiotherapy course. SECONDARY OBJECTIVES: I. To demonstrate the feasibility of monitoring daily step counts during a course of chemoradiotherapy in the setting of a multi-institutional trial. II. To examine the association between baseline activity level and clinical outcomes related to treatment tolerance, quality of life, chemoradiotherapy adverse events, and physical function preservation. III. To demonstrate associations between daily step counts and short-term hospitalization risk. IV. To explore predictors of step count decline during chemoradiotherapy among clinical factors and radiotherapy plan parameters. EXPLORATORY OBJECTIVES: I. To explore patterns of care regarding adjuvant immunotherapy administration following definitive chemoradiotherapy for locally advanced non-small cell lung cancer. II. To examine the association between baseline activity level with progression free survival and overall survival. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Usual Care ARM II: Usual Care + Continuous physical activity monitoring via a wearable device. Patients randomized to undergo activity monitoring will use a wearable device from the time of study enrollment until four weeks after the completion of thoracic radiotherapy.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
WellSpan Health - Chambersburg, Chambersburg, Pennsylvania, United States
WellSpan Health - Ephrata, Ephrata, Pennsylvania, United States
WellSpan Health - Gettysburg, Gettysburg, Pennsylvania, United States
WellSpan Health - Lebanon, Lebanon, Pennsylvania, United States
WellSpan Health - York, York, Pennsylvania, United States
Name: Nitin Ohri, MD
Affiliation: NRG Oncology
Role: PRINCIPAL_INVESTIGATOR